Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1982 1
1984 1
1985 2
1987 2
1988 1
1989 5
1991 2
1993 2
1994 2
1995 3
1996 2
1997 4
1998 2
1999 4
2000 2
2001 5
2002 2
2003 4
2004 8
2005 10
2006 8
2007 4
2008 6
2009 2
2010 12
2011 4
2012 5
2013 10
2014 12
2015 5
2016 3
2017 3
2018 3
2019 11
2020 9
2021 10
2022 7
2023 14
2024 7
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group. Kamoun A, et al. Among authors: radvanyi f. Eur Urol. 2020 Apr;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26. Eur Urol. 2020. PMID: 31563503 Free PMC article.
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, Duquesne I, Lavaud P, Nicotra C, Ngocamus M, Lacroix L, Tselikas L, Crehange G, Friboulet L, Castel-Ajgal Z, Neuzillet Y, Borcoman E, Beuzeboc P, Marret G, Gutman T, Wong J, Radvanyi F, Dureau S, Scoazec JY, Servant N, Allory Y, Besse B, Andre F, Le Tourneau C, Massard C, Bieche I. Loriot Y, et al. Among authors: radvanyi f. Nat Commun. 2024 Oct 4;15(1):8603. doi: 10.1038/s41467-024-52915-0. Nat Commun. 2024. PMID: 39366934 Free PMC article.
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Bussani R, Allory Y, van Rhijn BWG. Claps F, et al. Among authors: radvanyi f. BJU Int. 2023 Aug;132(2):170-180. doi: 10.1111/bju.15984. Epub 2023 Feb 20. BJU Int. 2023. PMID: 36748180 Free article.
Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.
Zugbi S, Aschero R, Ganiewich D, Cancela MB, Winter U, Ottaviani D, Sampor C, Dinardi M, Torbidoni AV, Mena M, Balaguer-Lluna L, Lamas G, Sgroi M, Lagomarsino E, Lubieniecki F, Fandiño A, Radvanyi F, Abramson DH, Podhajcer O, Llera AS, Cafferata EG, Chantada G, Carcaboso AM, Schaiquevich P. Zugbi S, et al. Among authors: radvanyi f. Invest Ophthalmol Vis Sci. 2023 Dec 1;64(15):27. doi: 10.1167/iovs.64.15.27. Invest Ophthalmol Vis Sci. 2023. PMID: 38117242 Free PMC article.
L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.
Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T. Neuzillet Y, et al. Among authors: radvanyi f. Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461580 French. No abstract available.
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ, Fontugne J, Moreno-Vega A, Meng XY, Groeneveld C, Dufour F, Kamoun A, Viborg Lindskrog S, Cabel L, Krucker C, Rapinat A, Dunois-Larde C, Lepage ML, Chapeaublanc E, Levrel O, Dixon V, Lebret T, Almeida A, De Reynies A, Rochel N, Dyrskjøt L, Allory Y, Radvanyi F, Bernard-Pierrot I. Shi MJ, et al. Among authors: radvanyi f. Eur Urol. 2023 Jan;83(1):70-81. doi: 10.1016/j.eururo.2022.09.030. Epub 2022 Oct 21. Eur Urol. 2023. PMID: 36273937 Free article.
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.
Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X, Vordos D, Guy L, Villers A, Schneider M, Coloby P, Lacoste J, Méjean A, Lacoste J, Descotes JL, Eschwege P, Loison G, Blanché H, Mariani O, Ghaleh B, Mangin A, Sirab N, Groussard K, Radvanyi F, Allory Y, Benhamou S. Lebret T, et al. Among authors: radvanyi f. BMJ Open. 2023 Dec 20;13(12):e075942. doi: 10.1136/bmjopen-2023-075942. BMJ Open. 2023. PMID: 38128940 Free PMC article.
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
Groeneveld CS, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Nicolle R, Chapeaublanc E, Poullet P, Jeffery D, Krucker C, Maillé P, Vacherot F, Vordos D, Benhamou S, Lebret T, Micheau O, Zinovyev A, Loew D, Allory Y, de Reyniès A, Bernard-Pierrot I, Radvanyi F. Groeneveld CS, et al. Among authors: radvanyi f. Eur Urol. 2024 May;85(5):483-494. doi: 10.1016/j.eururo.2023.05.037. Epub 2023 Jun 27. Eur Urol. 2024. PMID: 37380559 Free article.
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
Groeneveld CS, Pfister C, Culine S, Harter V, Krucker C, Fontugne J, Dixon V, Sirab N, Bernard-Pierrot I, de Reyniès A, Radvanyi F, Allory Y; VESPER trial investigators. Groeneveld CS, et al. Among authors: radvanyi f. Ann Oncol. 2025 Jan;36(1):89-98. doi: 10.1016/j.annonc.2024.09.008. Epub 2024 Sep 17. Ann Oncol. 2025. PMID: 39299443 Clinical Trial.
179 results